BioMed Research International / 2014 / Article / Tab 2

Research Article

Manufacturing Economics of Plant-Made Biologics: Case Studies in Therapeutic and Industrial Enzymes

Table 2

Capital cost factors for rBuChE case study.

Capital cost factors

Estimated based on PC (listed equipment PC plus unlisted equipment PC)
Unlisted equipment 0.2 listed purchased equipment cost

Direct costsPlant growthAgroproduction/infiltrationrBuChE recovery/purification

Piping0.1 PC0.35 PC0.35 PC
Instrumentation0.2 PC0.4PC0.4 PC
Insulation0.01PC0.03 PC0.03 PC
Electrical facilities0.1 PC0.1 PC0.1 PC
Building0.2 PC0.45 PC3 PC
Yard improvement0.15 PC0.15 PC0.15 PC
Auxiliary facilities0.1 PC0.4 PC0.4 PC
UE installation0.5 UEPC0.5 UEPC0.5 UEPC
Direct costs multiplicative factor2.352.885.43
Engineering0.25 DC0.25DC0.25 DC
Construction0.35 DC0.35 DC0.35 DC
Indirect costs multiplicative factor1.411.733.26
Contractors fee0.05 DC + IC0.05 DC + IC0.05 DC + IC
Contingency0.1 DC + IC0.1 DC + IC0.1 DC + IC
Other costs multiplicative factors for DFC0.560.691.30
Total multiplicative factor for DFC4.335.309.99
Total multiplicative factor for TCI (except working capital)4.545.5610.49

PC: purchase cost; DC: direct cost; IC: indirect cost; UEPC: unlisted equipment purchase cost; DFC: direct fixed capital; TCI: total capital investment.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.